Emmanuel de la Mora Jimenez

机构：Instituto Jalisciense de Cancerología

发表论文 15 篇 · 总被引 3580 次 · h-index 11

代表论文

• Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (2019 · New England Journal of Medicine · 被引 2875)
• Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 154)
• First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations (2022 · Journal of Thoracic Oncology · 被引 100)
• Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. (2023 · Journal of Clinical Oncology · 被引 94)
• Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial (2023 · Journal of Thoracic Oncology · 被引 55)
• First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1 (2021 · Journal of Thoracic Oncology · 被引 43)